

ABOUT HELIX BIOPHARMA

THE COMPANY




























Helix BioPharma Corp. is a Canadian, clinical-stage oncology company domiciled in Toronto, Ontario and listed on the TSX under the ticker symbol “HBP”, on OTC PINK under “HBPCD” and on FWB under the symbol “HBP0”.

The Company is on a mission to level the playing field against cancer’s biggest, most urgent challenges by **innovating from strength**.

At Helix, innovating from strength means taking a pragmatic approach to innovation; our growing, world-class team focuses its efforts on where we need a head start and which calculated risks are worth taking to bring effective, urgently needed treatments to patients battling prevalent, hard-to-treat cancers.

CORE TEAM

PREVIOUSLY:

	Thomas Mehrling, MD, PhD CEO	  
	Veronika Kandziora COO	  
	Rohit Babbar, CPA, CA CFO	  
	Davide Guggi, PhD CTO	  
	Brenda Lee, PhD Director: Clinical Operations	  
	Jonathan Davis, PhD Director: ADC Discovery	  
	Kim Gaspar, PhD Director: Quality Assurance	 



OUR VISION


To shape a near future where today’s hard-to-treat cancers are vincible.



OUR MISSION

To level the playing field against cancer’s biggest, most urgent challenges by honing young drug candidates with great potential and a head start into first- and best-in-class oncology medicines.

CANCERS WE ARE TARGETING, GLOBAL INCIDENCE (MILLIONS)



WHO GLOBOCAN, 2022

MORTALITY (DECEASED 5 YEARS FROM DIAGNOSIS)




American Cancer Society, (2024).

Brandwein et al., 2020.

Pancreatic Cancer Action Network (2024).

OUR ASSETS



CEACAM6 PLATFORM

Bio-conjugates that score with precision against prevalent, hard-to-treat cancers over-expressing carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6).

1) TUMOR DEFENCE BREAKER™, L-DOS47

An antibody-enzyme conjugate (AEC) that takes the brakes of anti-tumor immunity and delivers a game-changing assist to today’s leading immunotherapies.

2) C6 RDCs and ADCs

Radionuclide drug conjugates (RDCs) and bi-specific antibody-drug conjugates (ADCs) designed to outsmart resistant tumors expressing CEACAM6 and break new ground in therapeutic efficacy.

PRE-IND CANDIDATES

3) LEUMUNA™





An oral immune checkpoint modulator to bring long-term remission within reach for patients relapsing with leukemia after allogeneic stem cell transplantation.

4) GEMCEDA™

A first-in-class oral gemcitabine to enrich the spectrum of disease-limiting and life-enhancing outcomes for patients whose cancer has progressed.


HOW WE WANT TO MOVE THE NEEDLE

ASSETS IN ORDER OF STAGE OF DEVELOPMENT

CANDIDATE	L-DOS47	LEUMUNA™	GEMCEDA™	C6 RDCs & ADCs
LEAD INDICATION	 Non-small cell lung cancer (NSCLC)	 Leukemia relapse	 Advanced solid tumors	 Solid tumors
NEXT MILESTONE	PHASE IB IND (2025)	PHASE I/II IND (2026)	PHASE I/II IND (2026)	PATENT FILINGS (2025)
GOAL	Add ≥30% efficacy to checkpoint inhibitors	Long-term remission (2+ years) or cure	Significant increase in progression-free survival	Overcome resistance, maximize efficacy
PATENT LIFE	2036 + extensions	2041	2043	2045
HOW IT INNOVATES FROM STRENGTH	Enhances efficacy of latest standard of care (immunotherapy)	Backed by clinical safety and efficacy data + FDA Orphan Designation	WHO Essential Medicine with oral bioavailability on par with IV (90%)	Leveraging latest state-of-the-art ADC technology and CEACAM6 know-how

INVESTMENT & RETURN

CURRENTLY UNDERVALUED, WITH MAJOR VALUE INFLECTION POINTS APPROACHING





FOCUSED, AMBITIOUS PLAN AHEAD

- 1) USD 80 million capital raise
- 2) Phase IB in NSCLC first-patient-in in 2025
- 3) Relocation to the US and NASDAQ listing
- 4) Grow world-class team
- 5) Near-term partnering/exits

Shaping a near future where today's hard-to-treat cancers are **vincible**.

HELIX BIOPHARMA CORP.
 Bay Adelaide Centre – North Tower
 40 Temperance Street, Suite 2
 Toronto, ON M5H 0B4
 Tel: +1 857 208 7687
 Thomas Mehrling, CEO
corporate@helixbiopharma.com

TSX: HBP
 OTC PINK: HBPCD
 FRANKFURT: HBPO

 www.helixbiopharma.com
 [Helix BioPharma Corp.](https://www.linkedin.com/company/helixbiopharma)

For investor relations, contact
corporate@helixbiopharma.com